If I recall correctly, the 2a trial was a random cohort. An unexpected result from 2a was the results from patients suffering DKD. Although a statistically small group (10??), the results were promising and sent DMX-200 into a different tangent from just FSGS to a more significant 2b trial for DKD. This is what has me interested. How will the results go with a hand picked selection of suitable DKD patients? It could be awesome (or not)?
The DKD trial does not change the prospects for FSGS.
With regards to the recent CR, to me all the discussions on this subject and the reasoning behind it is just unfounded speculation. DXB has had many CR and if they didn't, the SP would not be where it is now. My single biggest investment in DXB was with the 12 cent CR which was highly criticised by some. Now 12 cents looks pretty good.
It's still a spec stock so who knows what the results will be, but I've been sitting on DXB for a long time, so I won't be spooked out of them this close to the finishing line.
cheers
Pies
If I recall correctly, the 2a trial was a random cohort. An...
Add DXB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
36.0¢ |
Change
0.025(7.46%) |
Mkt cap ! $197.8M | |||
| Open | High | Low | Value | Volume |
| 34.0¢ | 36.3¢ | 33.5¢ | $3.801M | 10.73M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 20000 | 36.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 36.5¢ | 378856 | 6 |
View Market Depth
| Last trade - 16.10pm 03/05/2024 (20 minute delay) ? |
|
|||||
|
Last
36.0¢ |
Change
0.025 ( 7.33 %) |
||||
| Open | High | Low | Volume | ||
| 33.5¢ | 36.5¢ | 33.5¢ | 5557634 | ||
| Last updated 15.58pm 03/05/2024 ? | |||||
| DXB (ASX) Chart |